Paybag
1.7K posts







$NBIS rocketing on Arete's coverage, which initiated a buy rating with a price target of $84 & their latest benchmark where they achieved industry-leading performance. Pushing a bit higher to a new ATH would give a great entry/accumulation point on the $40 retest.


If you're an investor in $NBIS and you're upset about this, you probably didn't do enough research in the first place. This was always expected to happen sooner or later. Management has repeatedly said that, given the capital-intensive nature of the business, additional funding would be required to support the hypergrowth phase. While the subsidiaries will help minimize dilution, they’re not enough on their own — and Arkady has always been clear that they’d also raise through the capital markets. Honestly, the terms were MUCH better than I expected. Just compare them to $CRWV's notes, you’ll see the difference. Some selling pressure today is natural, but in my view, this is a net positive development.























